Andere Sprachen Zymeworks Inc.

Aktien

A3DSSN

US98985Y1082

ZYME

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
8.51 ^USD	+1.19%		+1.19%	-18.09%

17.06.	Zymeworks gibt bekannt, dass die FDA den Antrag auf ein neues Prüfpräparat für eine Krebstherapie genehmigt hat	MT
12.06.	Transcript : Zymeworks Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:58 PM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy	17.06.
Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers	17.06.
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers	17.06.
Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer	10.06.
Sector Update: Health Care Stocks Decline Premarket Monday	10.06.
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy	10.06.
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer	10.06.
Zymeworks Announces Participation in Upcoming Investor Conferences	28.05.
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)	16.05.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	07.05.
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results	02.05.
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results	02.05.
Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Unlocking the potential of antibody drug conjugates	01.05.
Zymeworks Announces Participation in Upcoming Investor Conferences	30.04.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	28.04.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	20.04.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	12.04.
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024	11.04.
Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	08.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zymeworks Inc.

Aktien

A3DSSN

US98985Y1082

ZYME

Andere Sprachen

Filter